[Nooklerin (deanoli aceglumas) in the treatment of astenic and cognitive disorders in patients with borderline psychopatological conditions]. / Opyt primeneniia nooklerina (deanola atseglumat) pri terapii kognitivnykh i astenicheskikh rasstroistv u bol'nykh s pogranichnoi psikhicheskoi patologiei.

BACKGROUND: This work is devoted to the combined therapy of asthenic syndrome in psychiatric patients due to the importanmce of studies of clinical signs of asthenic disorders and their comorbidity with psychiatric and somatic diseases. AIM: To evaluate the efficacy and safety of deanoli aceglumas (nooklerin) in treatment of asthenic and cognitive disorders in patients with borderline psychopathological conditions. MATERIAL AND METHODS: Sixty patients were enrolled in the study (30 patients of the main group and 30 patients of the control group). All patients received psychopharmacological treatment. Nooklerin was administered as add-on in the daily dose of 1000 mg in the main group. Psychopathological and psychometric examinations were conducted. The duration of treatment with nooklerin was 30 days. RESULTS: There was a significant reduction of asthenic and cognitive disorders in the main group compared to the controls. The good tolerability of nooklerin in the absence of a negative effect on the main disease was shown. CONCLUSION: The possibility of using deanoli aceglumas (nooklerin) as a drug of choice in combined treatment of asthenic and cognitive disorders in patients with borderline psychopathological conditions is confirmed.

[Psychogenic depression and endogenous process (to the problem of reactive schizophrenia)].

OBJECTIVE: To conduct clinical differentiation of stress-induced conditions in schizophrenia and schizophrenia spectrum disorders according to the concept of so-called "Reactive schizophrenia" (J. Berze). MATERIAL AND METHODS: A sample consisted of 40 patients (14 male, 26 female, mean age 38.6±12.5. 17 years), including 17 (42%) patients with schizophrenia, 16 (40%) patients with ICD-10 schizotypal disorder and 7 (18%) patients with DSM-V schizotypal personality disorder. RESULTS AND CONCLUSION: All clinical cases were divided into two groups according to the discrepancy of endogenous/psychogenic factor interaction, clinical aspects and disease course. In the first group, the onset of stress-induced depression is due to psychogenic provocations of endogenous (schizophreniform) disorders. In the second group, the development of depression is based on the endogenous provocation of psychogenias (an increased affinity to stressful factors associated with the exacerbation of the endogenous process).